Tatva Chintan Pharma Chem Ltd

The investor presentation for Tatva Chintan Pharma Chem Limited (TATVA) for Q2 FY27 highlights a 76% year-over-year revenue growth, reaching ₹2,173 million, with a 19% EBITDA margin. The company achieved its highest-ever quarterly turnover, driven by growth in its Structured Directing Agents (SDA) and Phase Transfer Catalysts (PTC) segments. However, EBITDA remained stable due to temporary factors like solvent price hikes (60%-100% increase) and global freight costs (over 100% increase in US and Europe), which are expected to normalize by Q3 FY27. The presentation notes strong performance in SDA, supported by the implementation of EURO 7 emission standards, and progress in energy storage initiatives. The Pharma, Agro, and Specialty Chemicals business is gaining momentum, with new products contributing to revenue. The company emphasizes sustainable practices, including green chemistry and zero liquid effluent discharge facilities. Management prioritizes maintaining revenue growth and converting it into sustainable profits, with confidence in long-term opportunities. The consolidated financials show a 60% year-over-year revenue increase for H1 FY27, with PAT margin at 9.7% and a debt-to-equity ratio of 4.30. The company also outlines its global presence, with subsidiaries in the US and Netherlands, and a diversified product portfolio across specialty chemicals.

The tone_label is Positive as the document emphasizes record revenue, growth in key segments, and confidence in long-term opportunities, despite temporary challenges.